China's New Guideline For Drug Pricing Favors Innovation And First-to-market Generics
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - The National Development and Reform Commission, China's powerful economic regulatory body, is collecting feedback from industry for a new drug pricing guideline, which details new rules for setting drug prices in China's changing healthcare system
You may also be interested in...
2013 China Outlook: Year Of The Snake To Bring Twists And Turns For Pharma
A sharp expansion in China’s Essential Drug List along with the National Drug Reimbursement List are among the twists and turns expected as the Year of the Snake is ushered in this February.
China To Further Squeeze Distribution Margins And Limit Drug Markups In Hospitals
The National People’s Congress and Chinese Peoples’ Political Consultative Conference will bring in March a variety of new policies and regulations that will impact the industry.
China To Further Squeeze Distribution Margins And Limit Drug Markups In Hospitals
The National People’s Congress and Chinese Peoples’ Political Consultative Conference will bring in March a variety of new policies and regulations that will impact the industry.